Home » Newsletters » BioWorld Science

BioWorld Science

July 5, 2013

View Archived Issues

The Medicines Company reports results from second phase III trial of oritavancin for ABSSSI

Results from phase III trials of dolutegravir presented

Etubics receives NIH grant to develop HPV vaccine

Covidien separates pharmaceuticals business

Array BioPharma commences phase III study of MEK-162 in LGSOC

FEN1 gene expression associated with adverse breast and ovarian cancer characteristics

Phase I study of OTS-167 to begin in the U.S.

Catabasis Pharmaceuticals synthesizes new agents for viral infections

Noninvasive method to determine the genetic basis of acquired resistance to cancer drugs

Purdue Pharma presents novel opioid receptor agonists and antagonists

VentiRx begins new phase II trial of VTX-2337 in combination therapy for head and neck cancer

Novavax reports encouraging topline results from phase I trial of RSV vaccine in the elderly

Avanir and OptiNose enter development and commercialization agreement

Initiation of a phase III study of ITK-1 in patients with prostate cancer

Markers of cancer response to treatments including bevacizumab identified

Phase I/II study of Pergamum's LL-37 in chronic leg ulcers meets primary endpoint

Blaze Bioscience and Fred Hutchinson Cancer Research Center enter optides agreement

Gates Foundation provides phase II funding to MicroCubes vaccine project

Nanobiotix receives funding from bpifrance as part of grant to support nanomedicine consortium

GSK set to initiate phase III study of ofatumumab in rare skin disorder

Australian group presents novel metal complexes for Alzheimer's disease

Merck & Co. presents new JAK3 inhibitors

R-Pharm acquires worldwide license to olokizumab from UCB

ANO3 gene mutations implicated in primary cranio-cervical dystonia

Researchers at Boehringer Ingelheim divulge new mGlu5 positive allosteric modulators

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...